Avoid shorting Twist Bioscience (TWST) solely because it looks expensive: the business is growing rapidly, though no buy target or timing was provided.
The speaker remains short Moderna (MRNA) at around $210, but offered no thesis, target, or timeframe, so this is not a well-supported trade to follow.
Do not add to Nektar Therapeutics (NKTR) based on these insights; the speaker is down about 50% and did not recommend buying more.

Twist Bioscience (TWST)

• Described as a real, rapidly growing business that has been compounding for a long time.
• The speaker said the stock is very expensive, but that strong growth can make a company difficult to short because growth may continue to catch up with bearish expectations.
• He acknowledged that Twist could eventually hit a wall, but said he did not want to try to time when that might happen.

Takeaways

• The discussion is cautiously positive about the business’s growth, while recognizing valuation risk.
• The speaker’s view was to avoid shorting a fast-growing company solely because its stock looks expensive; the transcript gives no price target or specific buy recommendation.

NVIDIA (NVDA)

• The discussion focused on mapping NVIDIA’s supply chain and customers, rather than making a direct recommendation on the stock.
• Customers named included Dell, Quanta, Foxconn, Microsoft, Meta, Oracle, Supermicro, Amazon, Wistron, and Hewlett Packard.
• Suppliers named included Taiwan Semiconductor Manufacturing Company (TSMC), SK Hynix, Micron, and Samsung.

Takeaways

• The conversation highlights the value of researching NVIDIA through its customers and suppliers, which may help investors understand how demand and supply-chain exposure extend beyond NVIDIA itself.
• No valuation view, price target, or specific action on NVIDIA was stated.

Nektar Therapeutics (NKTR)

• The speaker said he was down about 50% on Nektar and was still holding the position.
• He said he did not know the company well and, when asked about buying more, said he did not think it was a good idea.

Takeaways

• The speaker’s comments point to caution about adding to a large loss when he does not feel confident in his understanding of the company.
• His position was to continue holding, but the transcript does not provide a thesis for Nektar or explain why he remains invested.

Moderna (MRNA)

• The speaker said he was still short Moderna.
• He also reacted negatively to the stock being at $210, but gave no further explanation of the short thesis.

Takeaways

• This is a disclosed bearish position, not a fully explained investment case.
• The transcript provides no price target, timeline, or specific risk factors for the short.

Intel (INTC)

• The speaker said he had sold his Intel position. The other person in the conversation acknowledged the sale, but no reason was given.

Takeaways

• The transcript records a completed sale but does not provide enough context to infer whether it reflected a change in outlook, portfolio needs, or another reason.

Seagate Technology (STX)

• The speaker said he was holding STX, while a coworker had sold his position after taking a loss.
• The conversation described the coworker’s position as volatile, but did not provide a detailed view of Seagate’s business or valuation.

Takeaways

• The speaker’s own position was to hold, but the discussion offers no thesis or target to support that view.
• The mention of a loss underscores that the coworker’s experience should not be treated as evidence for or against the stock.

Recursion Pharmaceuticals (RXRX)

• Recursion was briefly used as an example of a stock that the speaker viewed as a case where “the market’s just stupid,” in contrast with Twist, which he described as a real business with meaningful growth.
• No specific position, valuation, or recommendation on Recursion was stated.

Takeaways

• The comparison suggests skepticism about the market’s assessment of Recursion, but the transcript does not provide enough detail to form an actionable investment view.